U.S. Army-funded research project to Evaluate Iclaprim24 Oct 2019 08:06
U.S. Army-funded research project to Evaluate Iclaprim Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology. The aerosol technology allows delivery of antibiotics painlessly and rapidly into skin and soft tissue with low-pressure and focused delivery. The research is being funded through a grant from the U.S. Department of Defense - Congressionally Directed Military Infectious Diseases Research Program to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield. The work will be led by Dr. Daniel Zurawski, Ph.D., Chief, Pathogenesis and Virulence, WRAIR/Wound Infections Dept./Bacterial Diseases Branch.